Immunic's Earnings Outlook
Portfolio Pulse from Benzinga Insights
Immunic (NASDAQ:IMUX) is scheduled to release its quarterly earnings report on February 22, 2024, with an expected EPS of $-0.51. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Immunic's past earnings performance shows a mixed pattern of beating and missing EPS estimates, with corresponding fluctuations in stock price. Currently, shares are trading at $1.355, reflecting a 33.76% decrease over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.
February 21, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Immunic is expected to report an EPS of $-0.51 for the upcoming quarter. Past performance shows a pattern of EPS beats and misses with corresponding stock price changes. Currently, the stock is down 33.76% over the last year, indicating bearish sentiment.
The expected EPS and past performance suggest a cautious outlook for IMUX. While an earnings beat could positively impact the stock, the overall bearish sentiment and recent performance indicate a neutral short-term impact. The focus will be on whether IMUX can surpass the EPS estimate and provide positive future guidance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100